BNGO Bionano Genomics Inc.: Enterprise Value-to-Revenue Multiple

Public company logo of Bionano (BNGO)

The development of Bionano Genomics, Inc. (BNGO) depends on the adoption rate of optical DNA mapping and the volume of grants. The EV/Sales ratio trend visualizes the market valuation of the business excluding debt, where the value 329.37 corresponds to the current metric. Global customer reach mitigates regional risks, while the current focus on cost minimization and software updates should enable the company to reach break-even.

Bionano Genomics Inc. (BNGO) EV/Sales Multiple: for the period 11/23/2025 - 11/20/2026

BNGO (Bionano Genomics Inc.): analytical breakdowns and indicator data

- share price and consensus valuation forecast:
- company stock capitalization data:
- money and cash flow information:
Fundamental valuation:Bionano Genomics Inc. BNGO
Manufactured product of Bionano Genomics

Fundamental asset screening requires analyzing business value inclusive of net debt, which allows for an objective assessment of a company's market price relative to its operating revenues. This enterprise value assessment via EV/Sales reflects the premium for the technological potential of Saphyr and the development of DNA analysis software algorithms, helping investors determine the extent of the overpayment for the innovation cycle of Bionano Genomics, Inc. (BNGO).

Competitor analysis for Bionano Genomics, Inc.

TEM (tempus.com) - Company Value to Revenue Ratio|qiagen.com (QGEN) - Enterprise Value-to-Revenue Ratio|Ionis (IONS) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio Repligen|Avidity (RNA) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple CRSP|Total Company Value-to-Revenue Ratio GeneDx|Enterprise Value-to-Revenue Ratio Ultragenyx RARE|Total Company Value-to-Revenue Ratio Beam Therapeutics (BEAM)|SRPT: Company Value to Revenue|Enterprise Value-to-Revenue Multiple Twist Bioscience|TXG (10x Genomics) - Company Value to Revenue|Intellia Therapeutics, Inc. (NTLA) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio Stoke Therapeutics Inc|BLFS: Business Value to Revenue|Company Value to Revenue WVE (Wave Life Sciences Corp)|Total Company Value-to-Revenue Ratio Maze Therapeutics Corp|Sionna Therapeutics Inc - Company Value to Revenue|PRME (primemedicine.com) - Enterprise Value to Sales Volume|TSHA - Enterprise Value-to-Revenue Ratio|QURE (uniQure) - Company Value to Revenue Ratio|MeiraGTx Corp (MGTX) - Enterprise Value-to-Revenue Ratio|Regenxbio - Business Value to Revenue|Enterprise Value-to-Revenue Ratio solidbio.com|Enterprise Value-to-Revenue Multiple ocugen.com OCGN|EV/Sales Multiple PACB|Benitec - Company Value to Revenue Ratio|Enterprise Value-to-Revenue Ratio Design Therapeutics DSGN|EV/Sales Multiple Rocket Pharmaceuticals RCKT|Enterprise Value to Sales Volume 4D Molecular Corp|LXEO: Enterprise Value-to-Revenue Ratio|KRRO (Korro Bio, Inc) - Company Value to Revenue|Editas Medicine (EDIT) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio Silence Therapeutics Inc.|Company Value to Revenue Ratio PRQR (proqr.com)|Enterprise Value-to-Revenue Ratio Codexis Bio (CDXS)|EV/Sales Multiple sangamo.com (SGMO)|Enterprise Value-to-Revenue Ratio nautilus.bio NAUT|Total Company Value-to-Revenue Ratio Metagenomi, Inc (MGX)|Precision BioSciences Inc. - EV/Sales Multiple|GBIO - EV/Sales Multiple|BOLD: EV/Sales Multiple|Company Value to Revenue Ratio XCUR|Enterprise Value-to-Revenue Ratio Imunon|Phio Pharmaceuticals - Enterprise Value to Sales Volume|Enterprise Value-to-Revenue Ratio Mustang Bio, Inc. (MBIO)|Total Company Value-to-Revenue Ratio TransCode Therapeutics, Inc.|Applied DNA Sciences - Company Value to Revenue|Total Company Value-to-Revenue Ratio bluebirdbio.com (BLUE)|IPA - Enterprise Value-to-Revenue Ratio|OMGA - EV/Sales Multiple|OMIC (Singular Genomics Systems, Inc.) - Company Value to Revenue|Regulus Therapeutics Inc - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Syros Pharmaceuticals|Company Value to Revenue Telesis Bio (TBIO)|EV/Sales Multiple TCON|UBX - Enterprise Value-to-Revenue Multiple